Skip to nav Skip to content

Moffitt doctors review a patient's mammogram

Many individuals with metastatic breast cancer participate in clinical trials to access new treatments that aren’t yet available in other settings. For instance, some patients elect to try novel immunotherapies and hormone-based therapies by enrolling in clinical studies. At the same time, researchers can determine if the therapies under study have the potential to become the future "gold standard" of breast cancer treatment.

At Moffitt Cancer Center, we approach clinical trials in the same way that we approach other types of treatment. Our oncologists:

  • Carefully evaluate each patient’s diagnosis to determine if he or she might be a good candidate for any of our open trials
  • Provide each patient with the detailed information he or she needs to decide whether to participate in a trial
  • Monitor the patient’s progress throughout the trial, making any modifications that might be beneficial (such as increasing or decreasing the dosage of a particular medication) in order to help ensure the best possible outcome
  • Take into account the patient’s quality of life, recommending any supportive care therapies that might be helpful or recommending that a patient withdraw from a trial if his or the tumor is not responding to the treatment

Through our clinical trials, Moffitt has helped thousands of patients find new sources of hope in their fight against cancer. Many of these individuals have complex diagnoses, such as metastatic breast cancer, that were once thought to have limited treatment options. As part of our commitment to improving outcomes for every individual with cancer, we’ve positioned ourselves firmly at the forefront of innovative research.

View Clinical Trials

If you’d like to find out if you are a candidate for one of Moffitt’s metastatic breast cancer clinical trials, call  1-813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form online. You do not need a physician’s referral to make an appointment at Moffitt.